⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

August 8, 2024BMC Infectious DiseasesOpen Access

Real-world evaluation of early remdesivir in high-risk COVID-19 outpatients during Omicron including BQ.1/BQ.1.1/XBB.1.5

Kyle C. Molina Brandon Webb Victoria Kennerley Laurel Beaty Tellen D. Bennett Nichole E. Carlson David Mayer Jennifer L. Peers Seth Russell Matthew K. Wynia Neil R. Aggarwal Adit A. Ginde

View Full Paper

Ask AI

Bookmark

Share

Abstract

A trial performed among unvaccinated, high-risk outpatients with COVID-19 during the delta period showed remdesivir reduced hospitalization. We used our real-world data platform to determine the effectiveness of remdesivir on reducing 28-day hospitalization among outpatients with mild-moderate COVID-19 during an Omicron period including BQ.1/BQ.1.1/XBB.1.5.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Molina et al. (2024) studied this question.

synapsesocial.com/papers/68e5cfeeb6db64358756608c https://doi.org/10.1186/s12879-024-09708-z

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Remdesivir: Effectiveness and Safety in Hospitalized COVID-19 Patients—Analysis of Retrospectively Collected Data from Daily Practice in the Omicron Variant Era and Comparison with the Pre-Omicron Period2025 · 1 citations
2Remdesivir: Real-World Effectiveness and Safety in Individuals Hospitalized for Non-COVID Reasons and Non-Hospitalized High-Risk Patients During the Omicron Era in GreeceCohort Study · 2026
3Real-world effectiveness of early remdesivir in reducing mortality among vulnerable patients hospitalized for COVID-19: Evidence for clinical pharmacists and inpatient care providersCohort Study · 2026 · 1 citations
4Real-world effectiveness of remdesivir in immunocompromised patients hospitalized due to SARS-CoV-2 Infection: Insights to inform pharmacy practiceCohort Study · 2026 · 1 citations
5Comparable outcomes of outpatient remdesivir and sotrovimab among high-risk patients with mild to moderate COVID-19 during the omicron BA.1 surge2024 · 4 citations